Clinical Trial Update: To Compare Efficacy and Safety Between CT-P10 and Rituxan in Patients With Low Tumour Burden Follicular Lymphoma [Phase 3]

View source ↗

Summary

Phase 3 trial comparing CT-P10 to Rituxan in low tumor burden follicular lymphoma has completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• CT-P10 (rituximab biosimilar)
• Rituxan (rituximab)

Snippet

Sponsor: Celltrion | Conditions: Follicular Lymphoma | Phase 3 | Status: COMPLETED | Results posted: 2021-04-08